Current problems with systemic treatment of advanced hepatocellular cancer

Current Problems in Cancer

Volumn 34, Issue 2, 2010, Pages 131-149

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; BEVACIZUMAB; CAPECITABINE; CD135 ANTIGEN; CETUXIMAB; CIXUTUMUMAB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; INDISULAM; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OXALIPLATIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RAF PROTEIN; RAPAMYCIN; SORAFENIB; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ALCOHOL CONSUMPTION; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; APOPTOSIS; ASCITES; ASTHENIA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME ABERRATION; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ESOPHAGUS HEMORRHAGE; ESOPHAGUS VARICES; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTRIC ULCER BLEEDING; GENE MUTATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HICCUP; HUMAN; HYPERTENSION; INTESTINE PERFORATION; KIDNEY CANCER; LEUKOPENIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; NEOVASCULARIZATION (PATHOLOGY);

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; PYRIDINES; SIGNAL TRANSDUCTION;

EID: 77955083432     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2010.03.001     Document Type: Review

References (101)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132(7):2557-76.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-91.
3. http://www.cancer.org/docroot/stt/stt_0.asp.
4. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234(1):63-70.
5. Takayama T, Makuuchi M, Hirohashi S, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatoly 1998;28(5):1241-6.
6. More E, Kaspa RT, Sheiner P, et al. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998;129(8):643-53.
7. Kew M. Hepatic tumors and cysts. In: Feldman M, Sleisenger M, Scharschmidt B, Klein S, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathology/ Diagnosis/Management (ed 6, vol 1). Philadelphia, PA: WB Saunders, 1998:1364-87.
8. Godley P, Sandler RS. Digestive diseases in the United States: epidemiology and impact. NIH publication no. 94-1447, 1994.
9. Llovet J, Ricci S, Mazzaferro V, et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2007;25(Suppl):18S.
10. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6(9):674-87.
11. Feo F, Frau M, Tomasi ML, et al. Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med Maywood 2009;234(7):726-36.
12. Thorgeirsson SS. Hunting for tumor suppressor genes in liver cancer. J Hepatol 2003;37(4):739-41.
13. Bruix J, Boix L, Sala M, et al. Focus on hepatocellular carcinoma. Cancer Cell 2004;5(3):215-9.
14. Villanueva A, Newell P, Chiang DY, et al. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27(1):55-76.
15. Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009;286(1):52-9.
16. Koike K. Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007;37 (Suppl 2):S115-20.
17. Chung YH, Kim JA, Song BC, et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000;89(5):977-82.
18. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3(6):573-88.
19. Wiesenauer CA, Yip-Schneider MT, Wang Y, et al. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 2004;198(3):410-21.
20. Osada S, Kanematsu M, Imai H, et al. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg 2005;201(3):405-11.
21. Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatoly 2005;41(2):307-14.
22. Alexia C, Fallot G, Lasfer M, et al. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004;68(6):1003-15.
23. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005;4(4):677-85.
24. Harada K, Shiota G, Kawasaki H. Transforming growth factor-alpha and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma. Liver 1999;19(4):318-25.
25. Okano J, Shiota G, Kawasaki H. Expression of hepatocyte growth factor (HGF) and HGF receptor (c-met) proteins in liver diseases: an immunohistochemical study. Liver 1999;19(2):151-9.
26. Yamaguchi R, Yano H, Iemura A, et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatoly 1998;28(1):68-77.
27. Calvisi DF, Ladu S, Gorden A, et al. Ubiquitous activation of Ras and Jak/STAT pathways in human HCC. Gastroenterology 2006;130(4):1117-28.
28. Bekaii-Saab T, Markowitz J, Prescott N, et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15(18):5895-901.
29. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006;25(27):3778-86.
30. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52(5):706-12.
31. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008;48(1):83-90.
32. Giambartolomei S, Covone F, Levrero M, et al. Sustained activation of the Raf/MEK/erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein. Oncogene 2001;20(20):2606-10.
33. Ahmad T, Eisen T. Kinase inhibition with bay 43-9006 in renal cell carcinoma. Clin Cancer Res 2004;10(18 Pt 2):6388S-92S.
34. Wilhelm SM, Carter C, Tang L, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the ref/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109.
35. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68(16):6779-88.
36. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(1):25-34.
37. Abou-Alfa GK, Knox J, et al. Final results of phase II, randomized, double-blind study of sorafenib plus doxorubicin and placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Eur J Cancer 2007;5(4):Abstract 3500.
38. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23(27):6657-63.
39. O'Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperatvie Oncology Group's study E1203. J Clin Oncol 2006;24:4143.
40. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110(3):581-9.
41. Gruenwald V, Wilkens L, Gebel M, et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol 2007;25: Abstract 4598.
42. O'Neil BH, Williams-Goff LW, Kauh J, et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2009;27(Suppl): Abstract e15574.
43. Louafi S, Hebbar M, Rosmorduc O, et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): results of the phase II study ERGO. J Clin Oncol 2007;25(18S):Abstract 4594.
44. O'Neil BH, Bernard SA, Goldberg RM, et al. Phase II study of oxliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008;26(suppl):Abstract 4604.
45. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110(5):1059-67.
46. Govindarajan R, Seigel E, Makhoul I, et al. Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(suppl):Abstract e15557.
47. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21(31):4863-71.
48. Huber AH, Weis WI. The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin. Cell 2001;105(3): 391-402.
49. Cha MY, Kim CM, Park YM, et al. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatoly 2004;39(6):1683-93.
50. Ding Q, Xia W, Liu JC, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005;19(2):159-70.
51. Fukutomi T, Zhou Y, Kawai S, et al. Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatoly 2005;41(5):1096-105.
52. Park JY, Park WS, Nam SW, et al. Mutations of beta-catenin and axing I genes are a late event in human hepatocellular carcinogenesis. Liver Int 2005;25(1):70-6.
53. Nomoto S, Kinoshita T, Kato K, et al. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer 2007;97(9):1260-5.
54. Lee TK, Poon RT, Yuen AP, et al. Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res 2006;12(18):5369-76.
55. Piao Z, Park C, Park JH, et al. Allelotype analysis of hepatocellular carcinoma. Int J Cancer 1998;75(1):29-33.
56. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120(7):1763-73.
57. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83.
58. Li W, Tan D, Zhang Z, et al. Activation of Akt-mTOR-p70s6k pathway in angiogenesis in hepatocellular carcinoma. Oncol Rep 2008;20(4):713-9.
59. Yu K, Toral-Barza L, Discafani C, et al. MTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8(3):249-58.
60. Fujiwara Y, Hoon DS, Yamada T, et al. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res 2000;91(3):287-92.
61. Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. J Hepatol 2007;45(1):42-52.
62. Hui IC, Tung EK, Sze KM, et al. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int 2009;30(1):65-75.
63. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51(4):725-33.
64. Chen L, Shiah HS, Chen CY, et al. Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients(pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(Suppl):Abstract 4587.
65. Decaens T, Luciani A, Itti E, et al. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. 2009 Gastrointestinal Cancers Symposium, 2009.
66. Campos LT, Stephenson J, Swan F, et al. Daily dose of perifosine less toxic than weekly and active in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2007;25(18S):15072.
67. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006;25(27):3787-800.
68. Mínguez B, Tovar V, Chiang D, et al. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol 2009;25(3):186-94.
69. Kishimoto Y, Morisawa T, Kitano M, et al. Loss of heterozygosity of the mannose 6-phosphate/insulin-like growth factor II receptor and p53 genes in human hepatocellular carcinoma. Hepatol Res 2001;20(1):68-83.
70. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drugs Discov 2009;4(1):54-72.
71. Rowinsky EK, Youssoufian H, Tonra JR, et al. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007;13(18 Pt 2):5549s-55s.
72. Sherr CJ. Growth factor-regulated G1 cyclins. Stem Cells 1994;12(Suppl 1):47-55, discussion 55-7.
73. McDonald ER 3rd, El-Deiry WS. Cell cycle control as a basis for cancer drug development (review). Int J Oncol 2000;16(5):871-86.
74. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350(6317):429-31.
75. Hsu IC, Tokiwa T, Bennett W, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993;14(5):987-92.
76. Feitelson MA, Zhu M, Duan LX, et al. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993;8(5):1109-17.
77. Fujimoto Y, Hampton LL, Wirth PJ, et al. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 1994;54(1):281-5.
78. Boige V, Laurent-Puig P. [Genetic alterations associated with hepatocellular carcinoma]. Gastroenterol Clin Biol 1997;21(1):34-44.
79. Nagai H, Pineau P, Tiollais P, et al. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14(24):2927-33.
80. Rizzolio F, Tuccinardi T, Caligiuri I, et al. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 2009, Epub ahead of print.
81. Takeo S, Arai H, Kusano N, et al. Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet Cytogenet 2001;130(2):127-32.
82. Schwartz J, Schwartz M, Lehrer D, et al. Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J Clin Oncol 2006;24(Suppl):4144.
83. Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007;25(18S):Abstract 4570.
84. Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010;102:981-6.
85. Sun W, Haller DG, Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol 2007;25(18S):Abstract 4574.
86. Abrams TJ, Lee LB, Murray LJ, et al. Sun11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2(5):471-8.
87. Zhu AX, Sahani DV, di Tomaso E, et al. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2007;25(18S):Abstract 4637.
88. Faivre S, Raymond E, Douillard J, et al. Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007;25:149s.
89. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult patients with metastatic or surgically unresectable hepatocellular carcinoma (HCC). In 2008 Gastrointestinal Cancer Symposium Abstract 267. Orlando, FL: American Society of Oncology, 25-27 January 2008, p. 202.
90. Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma (HCC): A multicenter phase II trail (SAKK77/06 and SASL 23). J Clin Oncol 2009;27(Suppl):Abstract 4591.
91. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 2005;41(12):773-84.
92. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90.
93. Shen Y, Shao Y, Hsu C, et al. A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2009;27(Suppl):Abstract 4589.
94. Petrini I, Lencioni M, Ricasoli M, et al. A phase II (PhII) trial of sorafenib (S) in combination with 5-fluorouracil (5FU) continuous infusion (c.i.) in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary data. J Clin Oncol 2009;27(Suppl):Abstract 4592.
95. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26 (18):2992-8.
96. Malka D, Dromian C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007;25(suppl):Abstract 4570.
97. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24(12):1898-903.
98. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27(6):843-50.
99. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009;64(4):777-83.
100. Raoul JL, Finn RS, Kang YK, et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatcellular carcinoma (HCC). J Clin Oncol 2009;27(Suppl):Abstract 4577.
101. Finn RS, Kang Y, Park J, et al. Phase II, open lable study of brivanib alaninate in patients with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. In 2009 Gastroinestinal Cancers Symposium Abstract 200. Orlando, FL: American Society of Oncology, 25-27, January 2009, p. 202.